G1 Therapeutics (GTHX) Received its Third Buy in a Row
Markets After Needham and H.C. Wainwright gave G1 Therapeutics (NASDAQ: GTHX) a Buy rating last month, the company received another Buy, this time from Raymond James. Analyst Dane Leone maintained a Buy rating on G1 Therapeutics today. The company’s shares closed last Wednesday at $22.63. According to TipRanks.com, Leone is a 5-star analyst with an average return of 15.6% and a 62.7% success rate. Leone covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Tarsus Pharmaceuticals, and Allogene Therapeutics. G1 Therapeutics has an analyst consensus of Strong Buy, ...
Source: markets.co